NextCure (NXTC) EBT Margin (2019 - 2020)
NextCure (NXTC) posted quarterly EBT Margin of 257.63% for Q1 2020, up 100066.0% year-over-year from N/an in Q2 2019, and up 57.11% quarter-over-quarter from 600.7% in Q4 2019.
NextCure (NXTC) EBT Margin (2019 - 2020) Analysis & Trends
NextCure's EBT Margin history runs 2 years deep, the most recent figure standing at 257.63% for Q1 2020.
- In Q1 2020, EBT Margin rose 100066.0% year-over-year to 257.63%; the TTM figure through Dec 2020 stood at 648.16% (up 130240.0% YoY), while the FY2020 annual figure was 348.55%, up 202761.0% from the prior year.
- EBT Margin for Q1 2020 stood at 257.63%, up from 600.7% in the prior quarter.
- The five-year high for EBT Margin was 257.63% in Q1 2020, with the low at 4110.23% in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 13.77% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -25.06% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -2.67% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 12.09% |
| 10 | NextCure | 33.72 Mn | 33.72 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | -257.63% |
| Dec 31, 2019 | -600.70% |
| Sep 30, 2019 | -4,110.23% |
| Jun 30, 2019 | -2,112.55% |
| Mar 31, 2019 | -1,258.29% |